Biotechnology Archives - NAI 500

Home
Biotechnology

Taimei Technology

Taimei Technology Raises $212 Million to Advance CRO/Life Science Software

October 18, 2019

Eisai

Eisai Approved to Launch Antiepileptic Drug in China

October 18, 2019

dMed

dMed Biopharma, a China, US, EU Clinical CRO, Raises $50 Million

October 16, 2019

San Diego’s Ansun Bio Closes $80 Million B Round from China Investors for Novel Antiviral

October 15, 2019

Kangpu

Kangpu Completes Phase I Trial of Cancer Immunomodulator

October 11, 2019

Harbour BioMed

Harbour BioMed Completes China Phase II Trial of Dry Eye Treatment

October 11, 2019

BJ Bio

BJ Bio Selects CMAB for CMC and Manufacturing of Cancer mAb

October 11, 2019

Chi-Med

Innovent and Chi-Med Add Second Chi-Med Drug to Combo Partnership

October 10, 2019

China Grand Pharma

China Grand Pharma Pays $30 Million for Majority Stake in US-Based OncoSec

October 10, 2019

Chenguang Biotech

Chenguang Biotech to Build USD30 Million Tomato Processing Plant in California

October 9, 2019

Chi-Med

Chi-Med Starts Global Trial of Syk Inhibitor In Lymphoma Patients

October 9, 2019

CTFH

CTFH and Insilico Form $200 Million AI-Based Drug Discovery Partnership

October 9, 2019

Cellular Biomedicine 西比曼生物

CBMG Announces Plans to Build US R&D Facility for Immunotherapies

October 8, 2019

Gene+

Beijing Gene+ Completes $28 Million B Round for Genetic Test Services

October 7, 2019

Innovent

Innovent Bio Completes $300 Million Secondary Offering in Hong Kong

October 4, 2019

UK-Based Tech Investor Notion Capital Raises $150 Million for New Fund

October 3, 2019

Merck’s Keytruda Approved as Monotherapy for Lung Cancer in China

October 3, 2019

Simcere

Simcere In-licenses Novel Gout Treatment from JW Pharma of Korea

October 2, 2019